A unifying approach for surrogate marker validation based on Prentice's criteria

Statistics in Medicine

Volumn 25, Issue 2, 2006, Pages 205-221

  Alonso, Ariel ^a   Molenberghs, Geert ^a   Geys, Helena ^b   Buyse, Marc ^c   Vangeneugden, Tony ^d  

^a HASSELT UNIVERSITY   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^d Virco BVBA   (Belgium)

Author keywords

Hierarchical model; Likelihood reduction factor; Prentice criteria; Surrogate endpoints

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ARTICLE; CANONICAL ANALYSIS; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION FUNCTION; DISEASE MARKER; EVALUATION; HUMAN; MEASUREMENT; METHODOLOGY; RETINA MACULA AGE RELATED DEGENERATION; SCHIZOPHRENIA; STATISTICAL ANALYSIS; VALIDATION PROCESS; VALIDITY; VISUAL ACUITY;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; DATA INTERPRETATION, STATISTICAL; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MACULAR DEGENERATION; META-ANALYSIS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SCHIZOPHRENIA; VISUAL ACUITY;

EID: 31344445418     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2315     Document Type: Article

References (20)

1. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogates endpoints: a basis for a rational approach. European Journal of Clinical Pharmacology 1992; 43:235-244.
2. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125:605-613.
3. Prentice R. Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 1989; 8:431-440.
4. Freedman L, Graubard B, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11:167-178.
5. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16:1515-1527.
6. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1:49-67.
7. Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M. Validation of surrogate endpoints in randomized trials with discrete outcomes. Biometrical Journal 2002; 44:1-15.
8. Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M, Vangeneugden T, Bijnens L. Validation of longitudinally measured surrogate marker for a time-to-event endpoint. Journal of Applied Statistics 2002; 30:235-247.
9. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1:465-480.
10. Alonso A, Geys H, Molenberghs G, Vangeneugden T. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements. Biometrical Journal 2003; 45:931-945.
11. Alonso A, Geys H, Molenberghs G. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach. Biometrics 2004; 60:845-853.
12. Cortiñas Abrahantes J, Molenberghs G, Burzykowksi T, Shkedy Z, Alonso Abad A, Renard D. Choice of hierarchical units in the evaluation of surrogate endpoints. Computational Statistics and Data Analysis 2004; 47:537-563.
13. Alonso A, Geys H, Molenberghs G, Vangeneugden T. Investigating the criterion validity of psychiatric symptom scales using surrogate marker validation methodology. Journal of Biopharmaceutical Statistics 2002; 12: 161-179.
14. Pharmacological Therapy for Macular Degeneration Study Group. Interferon α-IIA is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Archives of Ophthalmology 1997; 115:865-872.
15. Molenberghs G, Geys H, Buyse M. Evaluation of surrogate end-points in randomized experiments with mixed discrete and continuous outcomes. Statistics in Medicine 2001; 20:3023-3038.
16. Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Statistics in Medicine 1994; 13(9):955-968.
17. Galecki A. General class of covariance structures for two or more repeated factors in longitudinal data analysis. Communications in Statistics: Theory and Methods 1994; 23:3105-3119.
18. Kent J. Information gain and a general measure of correlation. Biometrika 1983; 70:163-173.
19. Verbyla AP, Cullis BR, Kenward MG, Welham SJ. The analysis of designed experiments and longitudinal data by using smoothing splines. Applied Statistics 1999; 48:269-311.
20. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54:186-201.